Clinical Trials on Chronic Lymphocytic Leukemia in Remission

Total 3539 results

Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; University Hospital Plymouth...

Unknown

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (CLARITY)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukaemia

United Kingdom
Roswell Park Cancer Institute

Withdrawn

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Celgene Corporation

Terminated

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
CABYC
Bayer; Genzyme, a Sanofi Company; Fundacion Clinic per a la Recerca Biomédica; Grupo... and other collaborators

Withdrawn

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia (R-CHOP)

Chronic Lymphocytic Leukaemia | Patients Resistant to a Purine Analogous | Patients Relapsed With Purines Therapy

Spain
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Terminated

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

B-cell Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic Lymphoma | Stage... and other conditions

United States
GlaxoSmithKline

Completed

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphoblastic

Japan
Philipps University Marburg Medical Center
Deutsche Krebshilfe e.V., Bonn (Germany); AOP Orphan Pharmaceuticals AG

Completed

ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (ENDURE-CML-IX)

Chronic Myeloid Leukemia in Remission

France, Germany
National Cancer Institute (NCI)

Terminated

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage... and other conditions

United States
Astellas Pharma International B.V.

Terminated

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Chronic Lymphocytic Leukaemia (CLL) | Indolent Non Hodgkin's Lymphoma (iNHL)

Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
Fred Hutchinson Cancer Research Center/University...

Withdrawn

Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia and other conditions

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Study on the Diagnosis and Management of CLL in Italy by GIMEMA

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type

Italy
Ohio State University Comprehensive Cancer Center
MorphoSys AG

Active, not recruiting

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic... and other conditions

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)

Acute Myeloid Leukemia in Remission

United States
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Northwestern University
GlaxoSmithKline; National Comprehensive Cancer Network

Active, not recruiting

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Sweden
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Untreated Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
University Hospital, Clermont-Ferrand

Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (RAVEN)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | CLL | Relapsed Chronic Lymphocytic Leukemia | Progressive Chronic Lymphocytic Leukemia

France
Hoffmann-La Roche

Completed

Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer

Serbia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Chronic Lymphocytic Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome | Adult Acute Lymphoblastic Leukemia in Remission | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Hackensack Meridian Health
Celgene Corporation

Terminated

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL (VZCLLPI0146)

Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Unknown

NK Cells in Cord Blood Transplantation

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia and other conditions

United States
Case Comprehensive Cancer Center
Cephalon

Terminated

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
Gruppo Italiano Studio Linfomi

Unknown

Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia Stage A(0) | Chronic Lymphocytic Leukemia Stage A(I) | Chronic Lymphocytic Leukemia Stage A(II)

Italy
AbbVie

Recruiting

A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

Cancer, Chronic Lymphocytic Leukemia (CLL)

Korea, Republic of
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
BeiGene

Recruiting

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia | Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

China
Medical College of Wisconsin

Recruiting

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Leukemia | Burkitt Lymphoma | Lymphoblastic Lymphoma | Myelodysplasia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Chronic Myelogenous Leukemia - Chronic Phase | Chronic Myelogenous Leukemia, Accelerated Phase | Biphenotypic Acute Leukemia | Burkitt Leukemia | Chronic... and other conditions

United States
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of New ABT-263 Formulations

Chronic Lymphocytic Leukemia | Lymphomas | Leukemias

United States
Jennifer R. Brown, MD, PhD
AstraZeneca; TG Therapeutics, Inc.

Active, not recruiting

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT)

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
French Innovative Leukemia Organisation
Roche Pharma AG

Completed

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

B-cell Chronic Lymphocytic Leukemia CLL

France
Onxeo

Completed

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

B-cell Chronic Lymphocytic Leukemia

United Kingdom
Piramal Enterprises Limited
Dana-Farber Cancer Institute; Norris Cotton Cancer Center

Suspended

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

United States
Abbott
Genentech, Inc.

Withdrawn

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

B-cell Chronic Lymphocytic Leukemia
University Hospital Tuebingen
GlaxoSmithKline

Recruiting

Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)

Chronic Lymphoid Leukemia in Relapse

Germany

Clinical Trials on Chronic Lymphocytic Leukemia in Remission

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations